MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals (” MyMD” or “the Company”), a scientific phase pharmaceutical firm dedicated to prolonging healthy and balanced lifespan, today introduced that the first patient has actually been enrolled in the Company’s Stage 2 professional trial of lead prospect MYMD-1, an oral immune regulatory authority drug, as a treatment for postponing aging and expanding healthy life expectancy.
The primary endpoint for the Phase 2 double-blind, placebo-controlled medical test is to attain a decrease in the flowing levels of (TNF-α), growth death variable receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the proteins in the body that trigger inflammation and also help trigger the procedure of aging. The secondary actions of the trial will be the safety, tolerability, as well as pharmacokinetics in this population of patients.
” In a Stage 1 clinical trial of MYMD-1, we demonstrated the medication’s statistically significant efficiency in minimizing levels of TNF-α, a principal in causing pathological aging, in the blood. The FDA has actually approved TNF-α decrease as the main endpoint for our Phase 2 research study, which our company believe placements us well for an effective Stage 2 end result,” claimed Chris Chapman, M.D., President, Director and also Principal Medical Police Officer of MyMD. “The initiation of client enrollment in this research advances our objective to slow the aging process, avoid loss of muscle mass tissue in aging, limitation frailty, as well as expand healthy and balanced lifespan.”
MyMD has actually stated that there are no FDA-approved medicines for dealing with aging disorders and also extending healthy and balanced lifespan people, a market expected to be a minimum of $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are the most prescribed medicines by revenue, a worldwide market of roughly $40 billion per year,2 as well as, according to Nature Aging journal,3 a slowdown in aging that would increase life expectancy by one year deserves $38 trillion as well as by ten years is worth $367 trillion.
In addition to aging, MYMD-1’s distinctive activity in regulating the body immune system as well as dealing with chronic inflammation is being developed for the treatment of autoimmune disease, including rheumatoid arthritis (RA), several sclerosis (MS), diabetes mellitus, and also inflammatory digestive tract disease.
” We plan to start composing methods for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The climbing occurrence of rheumatoid arthritis and also various other autoimmune and inflammatory conditions are driving demand for TNF preventions like MYMD-1, as well as our company believe our by mouth administered medication with really reduced poisoning would be turbulent to the $60 billion market for RA if approved by the FDA for this sign.”
Rheumatoid arthritis affects around 40 million people globally.4.
Initially established for autoimmune illness, MYMD-1’s primary purpose is to slow down the aging process, protect against sarcopenia and also frailty, and also expand healthy life expectancy. Since it can cross the blood-brain obstacle as well as access to the main nerve system (CNS), MYMD-1 is additionally placed to be a feasible treatment for brain-related conditions. Its mechanism of activity as well as effectiveness in diseases consisting of numerous sclerosis (MS) as well as thyroiditis have been researched through cooperations with numerous academic institutions. MYMD-1 is also revealing pledge in pre-clinical researches as a potential treatment for post- COVID-19 complications and also as an anti-fibrotic and anti-proliferation therapeutic.
MYMD-1 has shown performance in pre-clinical researches in regulating the body immune system by doing as a careful inhibitor of lump necrosis factor-alpha (TNF-α), a motorist of persistent inflammation. Unlike various other treatments, MYMD-1 has been shown in these pre-clinical research studies to selectively obstruct TNF-α when it ends up being overactivated in autoimmune illness and also cytokine tornados, but not block it from doing its regular task of being a very first responder to any type of regular sort of moderate infection. MYMD-1’s convenience of dental dosing is an additional differentiator contrasted to presently readily available TNF-α blockers, all of which need distribution by shot or infusion. No authorized TNF prevention has actually ever been dosed orally. Furthermore, the drug is not immunosuppressive and also has actually not been shown to trigger the major negative effects typical with conventional therapies that treat inflammation.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical company committed to extending healthy life expectancy, is focused on establishing two novel restorative systems that treat the root causes of illness as opposed to only addressing the symptoms. MYMD-1 is a drug platform based upon a professional phase little particle that controls the body immune system to manage TNF-α, which drives chronic swelling, and also various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, rise long life, and treat autoimmune diseases as well as COVID-19- connected depression. The Firm’s 2nd drug platform, Supera-CBD, is being created to deal with chronic pain, dependency as well as epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) and is being developed to attend to and also improve upon the rapidly expanding CBD market, which includes both FDA approved medications and CBD items not currently managed as medicines. For additional information, go to www.mymd.com.